IBDEI1M6 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,577,0)
 ;;=DIALYSIS^7^46
 ;;^UTILITY(U,$J,358.4,578,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^25^46
 ;;^UTILITY(U,$J,358.4,579,0)
 ;;=ESTABLISHED PATIENT^2^47
 ;;^UTILITY(U,$J,358.4,580,0)
 ;;=INJECTIONS/MEDICATION^13^48
 ;;^UTILITY(U,$J,358.4,581,0)
 ;;=OTHER^14^48
 ;;^UTILITY(U,$J,358.4,582,0)
 ;;=ALLERGY INJECTION^1^48
 ;;^UTILITY(U,$J,358.4,583,0)
 ;;=INJECTION ADMINISTRATION^12^48
 ;;^UTILITY(U,$J,358.4,584,0)
 ;;=IMMUNIZATION ADMINISTRATION ^8^48
 ;;^UTILITY(U,$J,358.4,585,0)
 ;;=CATHETER^3^48
 ;;^UTILITY(U,$J,358.4,586,0)
 ;;=CATH FLUSHES^4^48
 ;;^UTILITY(U,$J,358.4,587,0)
 ;;=PFT^15^48
 ;;^UTILITY(U,$J,358.4,588,0)
 ;;=EKG/HOLTER MONITOR^7^48
 ;;^UTILITY(U,$J,358.4,589,0)
 ;;=IMMUNIZATIONS^9^48
 ;;^UTILITY(U,$J,358.4,590,0)
 ;;=INFUSIONS^11^48
 ;;^UTILITY(U,$J,358.4,591,0)
 ;;=PICC^16^48
 ;;^UTILITY(U,$J,358.4,592,0)
 ;;=CHEMO AND OTH COMPLEX DRUGS^5^48
 ;;^UTILITY(U,$J,358.4,593,0)
 ;;=BLOOD TRANSFUSIONS^2^48
 ;;^UTILITY(U,$J,358.4,594,0)
 ;;=EDUCATION^6^48
 ;;^UTILITY(U,$J,358.4,595,0)
 ;;=PRESSURE ULCER^14^49
 ;;^UTILITY(U,$J,358.4,596,0)
 ;;=SKIN^19^49
 ;;^UTILITY(U,$J,358.4,597,0)
 ;;=SIGNS AND SYMPTOMS^1^49
 ;;^UTILITY(U,$J,358.4,598,0)
 ;;=CARDIO/VASCULAR^2^49
 ;;^UTILITY(U,$J,358.4,599,0)
 ;;=COUNSELING^3^49
 ;;^UTILITY(U,$J,358.4,600,0)
 ;;=ENDOCRINE,METABOLIC,NUTRITION^4^49
 ;;^UTILITY(U,$J,358.4,601,0)
 ;;=ENT^5^49
 ;;^UTILITY(U,$J,358.4,602,0)
 ;;=GASTROINTESTINAL^6^49
 ;;^UTILITY(U,$J,358.4,603,0)
 ;;=GENITOURINARY & RENAL^7^49
 ;;^UTILITY(U,$J,358.4,604,0)
 ;;=HEPATITIS^8^49
 ;;^UTILITY(U,$J,358.4,605,0)
 ;;=IMMUNIZATIONS^9^49
 ;;^UTILITY(U,$J,358.4,606,0)
 ;;=MUSCULOSKELETAL^10^49
 ;;^UTILITY(U,$J,358.4,607,0)
 ;;=NEUROLOGY^11^49
 ;;^UTILITY(U,$J,358.4,608,0)
 ;;=NURSING MISCELLANEOUS^12^49
 ;;^UTILITY(U,$J,358.4,609,0)
 ;;=PREVENTIVE MEDICINE^15^49
 ;;^UTILITY(U,$J,358.4,610,0)
 ;;=PULMONARY/RESPIRATORY^16^49
 ;;^UTILITY(U,$J,358.4,611,0)
 ;;=PSYCHIATRIC^17^49
 ;;^UTILITY(U,$J,358.4,612,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^20^49
 ;;^UTILITY(U,$J,358.4,613,0)
 ;;=OSTOMY STATUS^13^49
 ;;^UTILITY(U,$J,358.4,614,0)
 ;;=SCREENING^18^49
 ;;^UTILITY(U,$J,358.4,615,0)
 ;;=ESTABLISHED PATIENT^1^50
 ;;^UTILITY(U,$J,358.4,616,0)
 ;;=NEW PATIENT^2^50
 ;;^UTILITY(U,$J,358.4,617,0)
 ;;=CONSULTATION^3^50
 ;;^UTILITY(U,$J,358.4,618,0)
 ;;=DIABETES TYPE 2/TYPE 1^16^51
 ;;^UTILITY(U,$J,358.4,619,0)
 ;;=GLAUCOMA-LTG/PIGMENT/PSEUDOEX^20^51
 ;;^UTILITY(U,$J,358.4,620,0)
 ;;=LENS/CATARACT^7^51
 ;;^UTILITY(U,$J,358.4,621,0)
 ;;=LIDS/LASHES/DRY EYE^4^51
 ;;^UTILITY(U,$J,358.4,622,0)
 ;;=MACULA^8^51
 ;;^UTILITY(U,$J,358.4,623,0)
 ;;=RETINA-VASCULAR^10^51
 ;;^UTILITY(U,$J,358.4,624,0)
 ;;=REFRACTIVE/VF/OTHER^3^51
 ;;^UTILITY(U,$J,358.4,625,0)
 ;;=CATEGORIES OF VISION LOSS^2^51
 ;;^UTILITY(U,$J,358.4,626,0)
 ;;=GLOBE/ORBIT/PAIN^13^51
 ;;^UTILITY(U,$J,358.4,627,0)
 ;;=MOST FREQUENT^1^51
 ;;^UTILITY(U,$J,358.4,628,0)
 ;;=CONJUNCTIVA/SCLERA^5^51
 ;;^UTILITY(U,$J,358.4,629,0)
 ;;=CORNEA/PUPILS/IRIS^6^51
 ;;^UTILITY(U,$J,358.4,630,0)
 ;;=GLAUCOMA-OPEN ANGLE^19^51
 ;;^UTILITY(U,$J,358.4,631,0)
 ;;=GLAUCOMA-SUSPECT/OHTN^18^51
 ;;^UTILITY(U,$J,358.4,632,0)
 ;;=GLAUCOMA-OTHER^21^51
 ;;^UTILITY(U,$J,358.4,633,0)
 ;;=MACULA-AMD^9^51
 ;;^UTILITY(U,$J,358.4,634,0)
 ;;=CHOROID/RETINA/RD^11^51
 ;;^UTILITY(U,$J,358.4,635,0)
 ;;=VITREOUS^12^51
 ;;^UTILITY(U,$J,358.4,636,0)
 ;;=OPTIC NERVE/VISUAL PATHWAY^14^51
 ;;^UTILITY(U,$J,358.4,637,0)
 ;;=NEURO/STRABISMUS/EYE MOVEMENT^15^51
